Korean J Nucl Med.  2004 Dec;38(6):481-485.

The Role of PET in Staging Non-Small Cell Lung Cancer

Affiliations
  • 1Department of Nuclear Medicine, Inha University College of Medicine, Inchon, Korea. iyhyun@dragon.inha.ac.kr

Abstract

Lung cancer has become a leading cause of cancer death in Korea. Accurate staging of non-small cell lung cancer (NSCLC) is essential to the ability to offer a patient the most effective available treatment and the best estimate of prognosis. PET with F-18 fluorodeoxyglucose (FDG) is indicated for the nodal staging of NSCLC and detection of distant metastases. Use of PET for mediastinal staging should not be relied on as a sole staging modality, and positive findings should be confirmed by mediastinoscopy. FDG PET avoids futile surgery by a more accurate selection of patients, especially by the detection of unexpected distant metastases.

Keyword

F-18 fluorodeoxyglucose (FDG) ; non-small cell lung cancer (NSCLC) ; positron emission tomography (PET) ; staging

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Humans
Korea
Lung Neoplasms
Mediastinoscopy
Neoplasm Metastasis
Prognosis
Full Text Links
  • KJNM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr